POINT ROBERTS, WA -- (MARKET WIRE) -- 07/29/04 -- www.*********************.com, (HDS) an investment news portal for
the Homeland Defense and Security Sector, reports on treatments and
vaccines in an exclusive featured article "More Billions for
Biodefense -- Are vaccines the answer?" following the recent signing
of Project BioShield into law by the President. Project BioShield, a
$5.6 Billion bill that will stockpile new vaccines and develop
countermeasures to bioterrorism attacks, will fuel demand for
biological and chemical weapons detection and protection solutions.
Within the biodefense community the question is being raised whether
we should spend more on post-exposure treatments?

HDS does not make recommendations, but offers a unique, free
information portal to investors to research news, articles, interviews
and a growing list of participating public companies and featured
profiled companies within the sector including: Aethlon Medical, Inc.
(OTC BB: AEMD) and Markland Technologies, Inc. (OTC BB: MRKL).

More Billions for Biodefense -- Are vaccines the answer?

By Allen Gibson, *********************.com

With the recent signing by the President of the Project Bioshield Act
of 2004, the federal government has authorized $5.6 Billion dollars in
spending over the next ten years to increase American's security from
biological attack.

Already, the government has purchased smallpox and anthrax vaccines
-- 75 million doses in the case of anthrax -- as a key part of the
Bioshield initiative. But is this a case of "fighting the last war" or
defending against the last terror attack?

A report out of the University of Pittsburgh suggests that the life
sciences are at the beginning of a revolutionary period. Scientific
understanding of living systems and how to manipulate them is
expanding exponentially. The report, from The Center for Biosecurity
at the U of P, suggests our strategy should be "an ambitious and
aggressive scientific research, development, and production (R & D &
P) program that delivers the diagnostic technologies, medicines, and
vaccines needed to counter the range of bioweapons agents."

...The doctors in charge of education for the National Center for
Biodefense argue that less money should be spent on vaccine purchase
and development, and more on post-exposure treatments.

Vaccines, say Drs. Ken Alibek and Charles Bailey, aren't going to be
effective for civilian populations, since no one can know which
specific agent to guard against, and the drugs must be administered in
advance to be effective. Also, they say in a letter to the editor of
the Biosecurity and Bioterror newsletter, it is far easier and takes
fewer years to develop a weapons-grade disease than to produce a
vaccine against it.

The immediate relevancy of programs other than vaccines was vividly
demonstrated this July, when the FBI announced that Ricin compound
was introduced into some baby food jars on the west coast. Minute
amounts of Ricin can be fatal. The gaseous form of Ricin was used in
the deadly Tokyo subway attacks a few years ago. And no vaccine or
cure presently exists. Which means that new, non-vaccine; treatments
are needed now, and will be needed in the future.

One example of how biotech can be repurposed to address the bioterror
threat comes from Aethlon Medical (OTC BB: AEMD), who created a
"Hemopurifier" machine to strip viruses and toxins out of the blood
of infected patients. Originally designed to treat HIV and Hep C, the
company is now working with the National Center for Biodefense at
George Mason University to develop filtration devices that could be
used by both the military and civilian populations against Class A
bioterror agents. The Company will use new FDA rules to test the
devices on animal species and extrapolate safety data for humans,
since human tests are obviously not practicable.

Full article: www.*********************.com/Companies/HomelandDefense/Articles/Biodefense.asp

HDS Featured Companies: Biological and chemical weapons detection and
medical countermeasures: HDS is compensated by featured companies as
disclosed below.

Aethlon Medical, Inc. (OTC BB: AEMD) www.AethlonMedical.com is
pioneering the development of viral filtration devices that rapidly
reduce the presence of infectious disease and toxins in the body.
The Company is developing pathogen filtration devices to treat
infectious agents used in biological warfare and terrorism.

Markland Technologies, Inc. (OTC BB: MRKL) www.marklandtech.com. is
positioned in the chemical detection sector with its Shipboard
Automatic Chemical Agent Detection and Alarm System (ACADA). The ACADA
is an automatic chemical agent alarm system capable of detecting,
warning and identifying blister and nerve agents simultaneously. The
ACADA is man-portable, operates independently after system start-up,
provides an audible and visual alarm, and provides communication
interface to support battlefield automation systems.

HomelandDefenseStock.com list of public companies in the sector: www.*****************/Companies/HomelandDefense/Articles/StockList.asp

Disclaimer: ECON Corporate Services is the owner of the domain www.*********************.com.
The site does not make recommendations
but offers an information portal to investors to research news,
articles, and recent research. The site is currently compensated for
by its "featured companies." Markland Technologies, Inc. currently
pays ECON $10,000 per month. Markland has issued shares to ECON in
the past and these payments are for the purpose of including Markland
in articles and other promotions. Aethlon Medical, mentioned in this
article, pays $3000 per month plus restricted shares equivalent to
$5000 per month.

Disclaimer: www.*****************/About/Disclaimer.asp

*********************.com is a Registered WA Trade Name.

For more information contact:
Dawn Van Zant
Trevor Ruehs
Toll free: 800-665-0411
Email: dvanzant@*********************.com
truehs@*********************.com

------------------
Due Da Due......But Be Quick About It!!!!!

Wid ma mind on ma money an' ma money on ma mind!!!